Bristol Myers Squibb (CELG-RI) Income from Continuing Operations (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Income from Continuing Operations for 18 consecutive years, with 3316000000.0 the latest figure, recorded in Q2 2026.

• In Q2 2026, Income from Continuing Operations rose 152.55% year-over-year to 3316000000.0; the TTM figure through Jun 2026 stood at 9276000000.0 (up 83.1% YoY), while the FY2025 annual figure was 7056000000.0, up 178.99% from the prior year.
• Income from Continuing Operations grew to 3316000000.0 in Q2 2026 per CELG-RI's latest filing, from 2679000000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 3316000000.0 in Q2 2026 and bottomed at 11908000000.0 in Q1 2024.
• Historically, Income from Continuing Operations has averaged 1027944444.44 across 5 years, with a median of 1723000000.0 in 2023.
• Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 625.28% — and 2025, when it soared 1328.95%.
• Bristol Myers Squibb's Income from Continuing Operations stood at 2025000000.0 in 2022, then declined by 12.99% to 1762000000.0 in 2023, then slumped by 95.69% to 76000000.0 in 2024, then jumped by 1328.95% to 1086000000.0 in 2025, then surged by 205.34% to 3316000000.0 in 2026.
• Business Quant data shows CELG-RI's Income from Continuing Operations at 3316000000.0 in Q2 2026, 2679000000.0 in Q1 2026, and 1086000000.0 in Q4 2025.